News

Recce Pharmaceuticals Doses Subjects in Rapid Infusion Phase I/II UTI Clinical Trial of RECCE® 327 at Scientia Clinical Research

Dosing at Scientia Clinical Research has commenced with first male and female subjects dosed ahead of scheduleSubjects who received RECCE®…

1 year ago

LifeMD to Report Second Quarter 2023 Financial Results on August 9

NEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services,…

1 year ago

Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023

HOLLISTER, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents…

1 year ago

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023

BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company…

1 year ago

Oculis Announces to Present at Upcoming August Investor Conferences

ZUG, Switzerland, and BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company…

1 year ago

EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer

LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies,…

1 year ago

Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023

NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial…

1 year ago

Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder

Full recruitment secures the target number of completer patientsMultiple primary endpoints include reduction in agitation and aggression and overall disease…

1 year ago

Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) for Vascular Trauma Repair

-Top-line results planned to be released in third quarter 2023- -Trial results are intended to support Biologics License Application (BLA)…

1 year ago

Hydreight To Launch New Website Booking System And Nurse Dispatch Service Making IV Drip Therapy Bookings Faster And Easier

VANCOUVER, British Columbia and LAS VEGAS, July 26, 2023 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV:…

1 year ago